Arcturus Therapeutics Holdings Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARCT research report →
Range $20 – $41
Price Chart
About the company
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations.
- CEO
- Joseph E. Payne
- IPO
- 2013
- Employees
- 109
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on ARCT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $214.73M
- P/E
- -2.43
- Fwd P/E
- 2.48
- PEG
- 0.09
- P/S
- 8.69
- P/B
- 1.27
- EV/EBITDA
- -0.70
- Div Yield
- 0.00%
- Gross Margin
- 97.36%
- Op Margin
- -384.08%
- Net Margin
- -349.71%
- ROE
- -46.79%
- ROIC
- -50.27%
Latest fiscal year · YoY change
- Revenue
- $67.22M-51.4%
- Gross Profit
- $64.20M-53.6%
- Op Income
- $-74,955,000
- Net Income
- $-65,783,000+18.7%
- EPS
- $-2.40+20.0%
- OCF Growth
- -24.3%
- FCF Growth
- -23.4%
- 52W High
- $17.96
- 52W Low
- $5.50
- 50D MA
- $11.86
- 200D MA
- $9.12
- Beta
- 2.60
- RSI (14)
- 33
- Avg Volume
- 886.59K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Arcturus said Q3 was a milestone quarter, with clinical progress across OTC and CF, a new LUNAR 2.0 delivery platform, and a cash runway that management says extends through year-end 2028.· November 5, 2026
- ARCT-810 Phase II OTC data showed meaningful biomarker activity and was generally safe and well tolerated; the company says this supports the next-generation ARCT-2601 program.
- LUNAR 2.0 produced a 38-fold potency improvement in nonhuman primates versus the original LUNAR formulation, and Arcturus plans to start ARCT-2601 Phase II dosing next quarter.
- For CF, enrollment in Cohort 4 is accelerating in Israel and Turkey, with full enrollment expected by year-end and top-line data before the planned Q2 2027 full data presentation.
- Cash and equivalents were $184.8 million at September 30, 2026, and management reiterated a cash runway of over 2 years through year-end 2028.
- KOSTAIVE remains commercial in Japan, and Arcturus completed the transfer of EU and UK marketing authorization holder rights, opening the door to potential 2027 commercial activity there.
Revenue was $18.3 million for the third quarter of 2026 and $23.3 million for the first nine months of 2026, versus $17.2 million and $74.8 million in the comparable periods last year. Research and development expense was $17 million for the quarter and $56 million year-to-date, versus $23.3 million and $87.7 million last year; G&A was $10.5 million and $30.9 million versus $10.4 million and $32.1 million. Net loss was $7.4 million, or $0.26 per share, versus a net loss of $13.4 million, or $0.49 per share, in Q3 2025; year-to-date net loss was $58.2 million, or $2.05 per share, versus $36.7 million, or $1.35 per share. Cash and cash equivalents were $184.8 million as of September 30, 2026, down $46.1 million from December 31, 2025, primarily due to clinical development spending, partly offset by a $12 million payment from CSL Seqirus. Management did not provide revenue or EPS guidance, but did guide that ARCT-2601 Phase II dosing should begin in Q1 2027 with top-line data in the second half of 2027, and that ARCT-032 full Phase II CF data is planned for Q2 2027 after year-end enrollment completion.
Joe Payne framed the quarter as a transition to a more important development phase, emphasizing progress in liver and respiratory programs plus the launch of LUNAR 2.0. He repeatedly stressed that delivery is central to the company’s thesis, highlighting the 38-fold primate potency improvement and saying the team wants to prove how that translates in patients. His tone was confident and forward-looking, but he also emphasized disciplined execution and a focus on programs where Arcturus believes it can show differentiation.
Dennis Mulroy focused on the financial discipline side of the story. He cited $184.8 million in cash and cash equivalents at quarter-end, a $46.1 million decrease from December 31, 2025, and said the decline was mainly due to clinical development activities, partially offset by the $12 million CSL Seqirus payment. He also walked through lower R&D spending from reduced clinical and manufacturing activity and said the company remains disciplined on capital allocation while maintaining a cash runway of over 2 years through year-end 2028.
Analysts pressed management on the timing and size of CF and OTC data sets, how the CF go/no-go decision would work, and whether the CF study could support a Phase III start in 2027. Management clarified that CF top-line data will come before the full Q2 2027 presentation, that the full cohort is about 20 patients at 10 mg daily for 12 weeks, and that a 2027 Phase III start would be ambitious but possible if data and FDA discussions support it. On OTC, management said ARCT-2601 will enroll up to 6 subjects and that the company has had favorable Type C interactions with FDA; on safety, management said no severe significant safety events have triggered DSMC action in the CF study so far.
The bull case is that Arcturus now has multiple shots on goal with visible upcoming catalysts: CF data, ARCT-2601 Phase II initiation, and broader liver pipeline expansion. Management believes the 38-fold LUNAR 2.0 delivery improvement could materially strengthen the platform, while the balance sheet gives the company time to reach key milestones without near-term financing pressure.
The main risks are that the clinical readouts still need to validate the platform in patients, especially the translation of LUNAR 2.0 from primates to humans and the eventual efficacy/safety profile in CF and OTC. The company also acknowledged uncertainty around the exact timing of the CF go/no-go decision and said a 2027 Phase III start would be “speculative” rather than assured. Commercially, KOSTAIVE’s expansion outside Japan is still early, and U.S. commercialization remains partner-dependent.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.6%
- Shares Outstanding
- 28.82M
- Float Shares
- 26.41M
of shares held by institutions
140 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ark Investment Management LLC | 2.99M | ▲ 92.92K |
| Blackrock, Inc. | 2.69M | ▲ 80.80K |
| Vanguard Group Inc | 2.09M | ▲ 204.04K |
| Sumitomo Mitsui Trust Group, Inc. | 1.69M | ▼ 274.02K |
| Amova Asset Management Americas, Inc. | 1.69M | ▼ 271.35K |
| Federated Hermes, Inc. | 1.68M | ▼ 1.63M |
| Vanguard Capital Management LLC | 1.11M | ▼ 7.90K |
| Two Sigma Investments, LP | 1.09M | ▲ 9.35K |
| Vanguard Portfolio Management LLC | 861.24K | ▼ 90.33K |
| Aqr Capital Management LLC | 675.01K | ▲ 513.74K |
| Jacobs Levy Equity Management, Inc | 647.51K | ▲ 448.78K |
| Geode Capital Management, LLC | 620.10K | ▼ 73.56K |
Held by 181 ETFs
Biggest fund positions in ARCT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 5, 26 | HOLMES EDWARD W | other | 15,000 |
| Jun 5, 26 | FARRELL PETER C | other | 15,000 |
| Jun 5, 26 | BARLOW JAMES F | other | 15,000 |
| Jun 5, 26 | Markels John | other | 15,000 |
| Jun 5, 26 | Slaoui Moncef | other | 15,000 |
| Jun 5, 26 | Marquet Magda | other | 15,000 |
| Jun 5, 26 | Marantz Jing L. | other | 15,000 |
| May 1, 26 | MULROY DENNIS | other | 100,000 |
| May 1, 26 | MULROY DENNIS | other | 0 |
| Dec 17, 25 | Roberts Joseph | other | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ARCT coverage
Recent articles, reports, and earnings notes.
Want a deeper read on ARCT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration
businesswire.com · Nov 16
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
What Arcturus Therapeutics (ARCT) Said on Its Q3 Earnings Call
marketbeat.com · Nov 5
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 5
Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress
businesswire.com · Nov 5
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026
businesswire.com · Oct 26
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
zacks.com · Sep 28
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform
marketbeat.com · Sep 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
